Top

Published in:

Open Access 01-12-2015 | Research

Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery

Authors: Chandan Verma, Viriya Kaewkangsadan, Jennifer M Eremin, Gerard P Cowley, Mohammad Ilyas, Mohamed A El-Sheemy, Oleg Eremin

Published in: Journal of Translational Medicine | Issue 1/2015

Abstract

Background

NK cells contribute to tumour surveillance, inhibition of growth and dissemination by cytotoxicity, secretion of cytokines and interaction with immune cells. Their precise role in human breast cancer is unclear and the effect of therapy poorly studied. The purpose of our study was to characterise NK cells in women with large (≥3 cm) and locally advanced (T3–4, N1–2, M0) breast cancers (LLABCs) undergoing neoadjuvant chemotherapy (NAC) and surgery, and to ascertain their possible contribution to a pathological complete response (pCR).

Methods

Women with LLABCs (n = 25) and healthy female donors [HFDs (n = 10)] were studied. Pathological responses in the breast were assessed using established criteria. Blood samples were collected pre and post NAC and surgery. Flow cytometry and labelled monoclonal antibodies established absolute numbers (AbNs) and percentages (%) of NK cells, and expressing granzyme B/perforin and NKG2D. In vitro NK cytotoxicity was assessed and NK cells and cytokines (IL-2, INF-γ, TGF-β) documented in tumours using immunohistochemical techniques. Data was analysed by SPSS.

Results

Women with LLABCs had significantly reduced AbNs (160.00 ± 40.00 cells/µl) but not % of NK cells, compared with HFDs (NK: 266.78 ± 55.00 cells/µl; p = 0.020). NAC enhanced the AbN (p = 0.001) and % (p = 0.006) of NK cells in patients with good pathological responses. Granzyme B⁺/perforin⁺ cells were significantly reduced (43.41 ± 4.00%), compared with HFDs (60.26 ± 7.00%; p = 0.003). NAC increased the % in good (p = 0.006) and poor (p = 0.005) pathological responders. Pretreatment NK cytotoxicity was significantly reduced in good (37.80 ± 8.05%) and poor (22.80 ± 7.97%) responders (p = 0.001) but remained unchanged following NAC. NK-NKG2D⁺ cells were unaltered and unaffected by NAC; NKG2D expression was increased in patients with a pCR (p = 0.001). Surgery following NAC was not beneficial, except in those with a pCR. Tumour-infiltrating NK cells were infrequent but increased peritumourally (p = 0.005) showing a significant correlation (p = 0.004) between CD56⁺ cells and grade of response. Tumour cytokines had no effect.

Conclusion

Women with LLABCs have inhibited blood innate immunity, variably reversed by NAC (especially with tumour pCRs), which returned to pretreatment levels following surgery. These and in situ tumour findings suggest a role for NK cells in NAC-induced breast pCR.

Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M et al (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191(4):661–668PubMedCentralPubMedCrossRef

Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T et al (2007) Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 104(3):267–275. doi:10.1007/s10549-006-9416-4 PubMedCrossRef

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235–271. doi:10.1146/annurev-immunol-031210-101324 PubMedCrossRef

Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P et al (2006) Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells. Cancer Immunol Immunother 55(6):699–707. doi:10.1007/s00262-005-0043-4 PubMedCrossRef

Sungur CM, Murphy WJ (2014) Positive and negative regulation by NK cells in cancer. Crit Rev Oncog 19(1–2):57–66PubMedCentralPubMedCrossRef

Bernardini G, Santoni A (2014) The pathophysiological role of chemokines in the regulation of NK cell tissue homing. Crit Rev Oncog 19(1–2):77–90PubMedCrossRef

Roberti MP, Mordoh J, Levy EM (2012) Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol 3:375. doi:10.3389/fimmu.2012.00375 PubMedCentralPubMedCrossRef

Strayer DR, Carter WA, Mayberry SD, Pequignot E, Brodsky I (1984) Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 44(1):370–374PubMed

Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(9244):1795–1799. doi:10.1016/S0140-6736(00)03231-1 PubMedCrossRef

10.

Vaquer S, Jorda J, Lopez de la Osa E, Alvarez de los Heros J, Lopez-Garcia N, Alvarez de Mon M (1990) Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol 36(1):90–92PubMedCrossRef

11.

Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M et al (2003) Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 20(5):445–451. doi:10.1159/000072714 PubMedCrossRef

12.

Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K (2001) Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol 96(2):574–578. doi:10.1111/j.1572-0241.2001.03535.x PubMedCrossRef

13.

Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N et al (2011) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 17(4):678–689. doi:10.1158/1078-0432.CCR-10-2173 PubMedCrossRef

14.

Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G et al (2011) Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71(21):6621–6632. doi:10.1158/0008-5472.CAN-11-0792 PubMedCrossRef

15.

Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422. doi:10.1158/0008-5472.CAN-10-4179 PubMedCrossRef

16.

Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R et al (2012) Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) 90(1):55–66. doi:10.1007/s00109-011-0806-7 CrossRef

17.

Sznurkowski JJ, Zawrocki A, Biernat W (2014) Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma. Cancer Immunol Immunother 63(3):297–303. doi:10.1007/s00262-013-1511-x PubMedCentralPubMedCrossRef

18.

Garrido F, Cabrera T, Aptsiauri N (2010) “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249–256. doi:10.1002/ijc.25270 PubMed

19.

Hoglund P, Brodin P (2010) Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 10(10):724–734. doi:10.1038/nri2835 PubMedCrossRef

20.

Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239–252. doi:10.1038/nri3174 PubMedCrossRef

21.

Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N (2012) Natural killer cells in non-hematopoietic malignancies. Front Immunol 3:395. doi:10.3389/fimmu.2012.00395 PubMedCentralPubMedCrossRef

22.

Bonavida B (2014) NK cell phenotypic and functional heterogeneities and molecular mechanisms of cytotoxicity. Crit Rev Oncog 19(1–2):21–45PubMedCrossRef

23.

Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C et al (2009) Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 69(8):3563–3569. doi:10.1158/0008-5472.CAN-08-3807 PubMedCrossRef

24.

Ferlazzo G, Moretta L (2014) Dendritic cell editing by natural killer cells. Crit Rev Oncog 19(1–2):67–75PubMedCrossRef

25.

Garner WL, Minton JP, James AG, Hoffmann CC (1983) Human breast cancer and impaired NK cell function. J Surg Oncol 24(1):64–66PubMedCrossRef

26.

Konjevic G, Jurisic V, Spuzic I (2001) Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 66(3):255–263PubMedCrossRef

27.

Konjevic G, Radenkovic S, Srdic T, Jurisic V, Stamatovic L, Milovic M (2011) Association of decreased NK cell activity and IFNgamma expression with pSTAT dysregulation in breast cancer patients. J BUON 16(2):219–226PubMed

28.

Eremin O, Coombs RR, Ashby J (1981) Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer 44(2):166–176PubMedCentralPubMedCrossRef

29.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59–73. doi:10.1038/nri2216 PubMedCrossRef

30.

Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58(3):317–324. doi:10.1007/s00262-008-0576-4 PubMedCrossRef

31.

Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21–27. doi:10.1038/sj.bjc.6600347 PubMedCentralPubMedCrossRef

32.

Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102(1):115–123. doi:10.1038/sj.bjc.6605465 PubMedCentralPubMedCrossRef

33.

Bubenik J (2004) MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 25(2):487–491PubMed

34.

Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M et al (2011) Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 11:179. doi:10.1186/1471-2407-11-179 PubMedCentralPubMedCrossRef

35.

Brittenden J, Heys SD, Ross J, Park KG, Eremin O (1994) Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of l-arginine supplementation. Eur J Surg Oncol 20(4):467–472PubMed

36.

Khan AL, Richardson S, Drew J, Larsen F, Campbell M, Heys SD et al (1995) Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery 118(3):531–538PubMedCrossRef

37.

Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113. doi:10.1200/JCO.2009.23.7370 PubMedCrossRef

38.

Murta EF, de Andrade JM, Falcao RP, Bighetti S (2000) Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86(5):403–407PubMed

39.

Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E et al (2011) A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res 13(6):R117. doi:10.1186/bcr3060 PubMedCentralPubMedCrossRef

40.

Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G et al (2004) Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 53(12):1146–1152. doi:10.1007/s00262-004-0556-2 PubMedCrossRef

41.

Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J et al (2013) Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol 190(5):2424–2436. doi:10.4049/jimmunol.1200140 PubMedCrossRef

42.

Beitsch P, Lotzova E, Hortobagyi G, Pollock R (1994) Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg Oncol 3(4):211–219PubMedCrossRef

43.

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19(5):1508–1516. doi:10.1245/s10434-011-2108-2 PubMedCrossRef

44.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. doi:10.1200/JCO.2011.38.8595 CrossRef

45.

Eremin J, Cowley G, Walker LG, Murray E, Stovickova M, Eremin O (2015) Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival. Springerplus Oncol 4:9. doi:10.1186/2193-1801-4-9

46.

Eremin O, Ashby J, Stephens JP (1978) Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer 21(1):35–41PubMedCrossRef

47.

Mackay IR, Goodyear MD, Riglar C, Penschow J (1983) Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer Immunol Immunother 16(2):98–100PubMedCrossRef

48.

Cunningham-Rundles S, Filippa DA, Braun DW Jr, Antonelli P, Ashikari H (1981) Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst 67(3):585–590PubMed

49.

White D, Jones DB, Cooke T, Kirkham N (1982) Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer 46(4):611–616PubMedCentralPubMedCrossRef

50.

Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N et al (2009) Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother 63(9):703–706. doi:10.1016/j.biopha.2009.02.003 PubMedCrossRef

51.

Konjevic G, Jurisic V, Jovic V, Vuletic A, Mirjacic Martinovic K, Radenkovic S et al (2012) Investigation of NK cell function and their modulation in different malignancies. Immunol Res 52(1–2):139–156. doi:10.1007/s12026-012-8285-7 PubMedCrossRef

52.

Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A et al (2008) Breast cancer and the immune system. J Soc Integr Oncol 6(4):158–168PubMedCentralPubMed

53.

Tichatschek E, Zielinski CC, Muller C, Sevelda P, Kubista E, Czerwenka K et al (1988) Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother 27(3):278–282PubMedCrossRef

54.

Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49(4–5):181–185PubMedCrossRef

55.

Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17(4):616–623. doi:10.1038/cdd.2009.206 PubMedCrossRef

56.

Ewen CL, Kane KP, Bleackley RC (2012) A quarter century of granzymes. Cell Death Differ 19(1):28–35. doi:10.1038/cdd.2011.153 PubMedCentralPubMedCrossRef

57.

Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA (2012) Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 33(8):406–412. doi:10.1016/j.it.2012.04.001 PubMedCrossRef

58.

Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E et al (2007) T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26(3):311–321. doi:10.1016/j.immuni.2007.01.016 PubMedCrossRef

59.

Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31(1):84–98. doi:10.1016/j.immuni.2009.05.007 PubMedCrossRef

60.

Zhou L, Wang H, Zhong X, Jin Y, Mi QS, Sharma A et al (2008) The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells. Genome Biol 9(7):R119. doi:10.1186/gb-2008-9-7-r119 PubMedCentralPubMedCrossRef

61.

Hodge G, Hodge S, Li-Liew C, Reynolds PN, Holmes M (2012) Increased natural killer T-like cells are a major source of pro-inflammatory cytokines and granzymes in lung transplant recipients. Respirology 17(1):155–163. doi:10.1111/j.1440-1843.2011.02075.x PubMedCrossRef

62.

Piroozmand A, Hassan ZM (2010) Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther 6(4):478–481. doi:10.4103/0973-1482.77110 PubMedCrossRef

63.

Obeidy P, Sharland AF (2009) NKG2D and its ligands. Int J Biochem Cell Biol 41(12):2364–2367. doi:10.1016/j.biocel.2009.07.005 PubMedCrossRef

64.

Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I et al (2009) Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124(7):1594–1604. doi:10.1002/ijc.24098 PubMedCrossRef

65.

Zafirova B, Wensveen FM, Gulin M, Polic B (2011) Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 68(21):3519–3529. doi:10.1007/s00018-011-0797-0 PubMedCentralPubMedCrossRef

66.

Zhang J, Basher F, Wu JD (2015) NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol 6:97. doi:10.3389/fimmu.2015.00097 PubMedCentralPubMedCrossRef

67.

Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3(10):781–790. doi:10.1038/nri1199 PubMedCrossRef

68.

Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1(2):119–126. doi:10.1038/77793 PubMedCrossRef

69.

Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202(5):583–588. doi:10.1084/jem.20050994 PubMedCentralPubMedCrossRef

70.

Marcais A, Viel S, Grau M, Henry T, Marvel J, Walzer T (2013) Regulation of mouse NK cell development and function by cytokines. Front Immunol 4:450. doi:10.3389/fimmu.2013.00450 PubMedCentralPubMedCrossRef

71.

Song H, Hur DY, Kim KE, Park H, Kim T, Kim CW et al (2006) IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol 242(1):39–45. doi:10.1016/j.cellimm.2006.09.002 PubMedCrossRef

72.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62(21):6178–6186PubMed

73.

de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA et al (2012) NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12:24. doi:10.1186/1471-2407-12-24 PubMedCentralPubMedCrossRef

74.

Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA et al (2013) Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 11:16. doi:10.1186/1479-5876-11-16 PubMedCentralPubMedCrossRef

75.

Raulet DH, Vance RE, McMahon CW (2001) Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19:291–330. doi:10.1146/annurev.immunol.19.1.291 PubMedCrossRef

76.

Trowsdale J, Parham P (2004) Mini-review: defense strategies and immunity-related genes. Eur J Immunol 34(1):7–17. doi:10.1002/eji.200324693 PubMedCrossRef

77.

Watzl C, Long EO (2003) Natural killer cell inhibitory receptors block actin cytoskeleton-dependent recruitment of 2B4 (CD244) to lipid rafts. J Exp Med 197(1):77–85PubMedCentralPubMedCrossRef

78.

Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C et al (2010) NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 185(10):5732–5742. doi:10.4049/jimmunol.1002092 PubMedCentralPubMedCrossRef

79.

Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR et al (2013) Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest 123(10):4410–4422. doi:10.1172/JCI69369 PubMedCentralPubMedCrossRef

80.

Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF et al (2007) Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 7:17PubMedCentralPubMed

81.

Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A et al (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72(6):1407–1415. doi:10.1158/0008-5472.CAN-11-2544 PubMedCrossRef

82.

Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC (2012) Melanoma cells inhibit NK cell functions. Cancer Res 72(20):5428–5429. doi:10.1158/0008-5472.CAN-12-1181 (author reply 30) PubMedCrossRef

83.

Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE et al (2005) Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6(9):928–937. doi:10.1038/ni1239 PubMedCrossRef

84.

Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, Benevolo M et al (2013) T and NK cells: two sides of tumor immunoevasion. J Transl Med 11(1):30. doi:10.1186/1479-5876-11-30 PubMedCentralPubMedCrossRef

85.

Aloysius MM, Walker LG, Eremin O (2011) Cancer and the immune response, Chap 4. In: Eremin O, Sewell H (eds) Essential immunology for surgeons. Oxford OUP, Oxford, pp 236–300

Title: Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery
Authors: Chandan Verma
Viriya Kaewkangsadan
Jennifer M Eremin
Gerard P Cowley
Mohammad Ilyas
Mohamed A El-Sheemy
Oleg Eremin
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-015-0535-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells

Increased CD160 expression on circulating natural killer cells in atherogenesis

Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene

Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres

Evaluation of the anaphylactoid potential of Andrographis paniculata extracts using the popliteal lymph node assay and P815 cell degranulation in vitro

T1ρ MRI of healthy and fibrotic human livers at 1.5 T

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page